Jefferies Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jefferies Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$858K	Buy	+15,000	New	+$822K	0.01%	1037
2024 Q2	–	Sell	-7,500	Closed	-$655K	–	1434
2024 Q1	$655K	Sell	7,500 -29,000	-79%	-$2.6M	0.01%	960
2023 Q4	$3.52M	Buy	36,500 +14,200	+64%	+$1.26M	0.02%	512
2023 Q3	$1.97M	Buy	22,300 +12,300	+123%	+$1.09M	0.02%	628
2023 Q2	$867K	Hold	10,000	–	–	0.01%	981
2023 Q1	$972K	Sell	10,000 -5,100	-34%	-$529K	0.01%	904
2022 Q4	$1.56M	Buy	+15,100	New	+$1.42M	0.01%	740

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Jefferies Financial Group's BMRN Position: Q2 2026 in Review

Jefferies Financial Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.4% in Q2 2026, selling an estimated $103K and leaving 466,258 shares worth $26.7M. The position accounts for 0.18% of the portfolio, ranked #113.

Jefferies Financial Group first reported a position in BMRN in Q4 2022 and has held it in 11 quarters since. The position peaked at $27.8M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Jefferies Financial Group held 466,258 shares of BioMarin Pharmaceuticals worth $26.7M as of Q2 2026.
Jefferies Financial Group sold 1,888 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $103K.
BioMarin Pharmaceuticals made up 0.18% of Jefferies Financial Group's portfolio in Q2 2026, its #113 holding.
Jefferies Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Jefferies Financial Group's BioMarin Pharmaceuticals position peaked at $27.8M in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.